Literature DB >> 3484891

HLA-DR3 antigen linkage in patients with hypertrophic obstructive cardiomyopathy.

S Fiorito, C Autore, P V Fragola, M Purpura, D Cannata, M Sangiorgi.   

Abstract

In order to investigate if genetic factors could be involved in the pathogenesis of hypertrophic obstructive cardiomyopathy, we determined HLA-A, HLA-B, HLA-C, and HLA-DR specificities in 12 Italian patients affected with the disease and in healthy family members of one of them. HLA-DR3 was found in 50% of patients as compared to 17.1% of normal control subjects (p = 0.023, relative risk = 4.82). The two relatives also had HLA-DR3 antigen and, in addition, showed equivocal signs of hypertrophy at echocardiographic examination. Thus hypertrophic obstructive cardiomyopathy is associated with genes in the HLA-DR region, and immunogenetic factors could be involved in the pathogenesis of the disease. Furthermore, the minimal target organ abnormalities in "healthy" relatives could represent a subclinical stage of the disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3484891     DOI: 10.1016/0002-8703(86)90558-2

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  HLA gene analysis in a Japanese family with hypertrophic cardiomyopathy by restriction fragment length polymorphism.

Authors:  T Kanda; N Takeuchi; A Hasegawa; T Suzuki; K Murata
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

2.  Hypertrophic cardiomyopathy and systemic lupus erythematosus.

Authors:  J Ara; J Vivancos; J Soler-Carrillo; J C Paré; R Cervera; J Font
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  HLA antigens in idiopathic dilated cardiomyopathy.

Authors:  C J Limas; C Limas
Journal:  Br Heart J       Date:  1989-11

4.  Hypertrophic cardiomyopathy in systemic sclerosis. A report of two cases.

Authors:  I Moyssakis; D P Papadopoulos; G Anastasiadis; P Vlachoyannopoulos
Journal:  Clin Rheumatol       Date:  2005-10-12       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.